

Contents

Nanomedicine: Present Accomplishments and Far-Reaching Promises *XXI*

Part One Introduction to Nanoscience in Medicine of the Twenty-First Century *1*

- 1 Challenges and Opportunities of Nanotechnology for Human Health** *3*
Bert Müller
 References *6*
- 2 Nanoscience and Nanotechnology and the Armory for the Twenty-First Century Health Care** *9*
Marcel Van de Voorde and Pankaj Vadgama
- 2.1 Conceptual Dream *9*
 2.2 A Real World Encounter *9*
 2.3 Mapping the Microcosm of Disease *10*
 2.4 Delivery at the Clinical “Coal Face” *10*
 2.5 A High Precision Aim for Disease Targets *10*
 2.6 A Materials Revolution for Clinical Care *11*
 2.7 Robotics for Microrepair and Healing *12*
 2.8 A Dialog with Cells *12*
 2.9 Stealth Materials for a More Potent Delivery *13*
 2.10 Improved Biointerrogation for a Better Understanding *13*
 2.11 Crossing the Structure–Function Threshold *14*
 2.12 Living Implants for a Living Matrix *15*
 2.13 Taming the Nanointerface *15*
 2.14 Where are We Now? *16*
 2.15 Where will the Revolution Take Us? *16*
 2.16 Conclusions *17*
 References *18*

3 Nanomedicine Activities in the United States and Worldwide 21

Carlotta Borsoi, Joy Wolfram, and Mauro Ferrari

- 3.1 Drug Delivery 22
 - 3.1.1 Strategies for Localized Delivery of Nanoparticles 23
 - 3.1.1.1 Physical Targeting 24
 - 3.1.1.2 Biomaterials 25
 - 3.1.1.3 Molecular Targeting 26
 - 3.1.1.4 External Activation 26
 - 3.1.2 Next-generation Drug Delivery Vehicles 27
 - 3.1.2.1 Sequential Drug Delivery 27
 - 3.1.2.2 Amplified Drug Delivery 29
 - 3.1.2.3 Biomimicry 29
 - 3.1.3 Implantable Devices 30
- 3.2 Diagnostics 31
- 3.3 Scaffolds 33
 - 3.3.1 Bone Tissue Regeneration 34
 - 3.3.2 Skin Regeneration 35
 - 3.3.3 Nerve Regeneration 36
- 3.4 Clinically Approved Nanoproducts 37
- References 39

Part Two Leading Cause of Death: Cardiovascular Diseases 51

4 Challenges in Cardiovascular Treatments Using Nanotechnology-Based Approaches 53

Till Saxer and Margaret N. Holme

- 4.1 Introduction 53
- 4.2 Unmet Needs in Cardiology 54
 - 4.2.1 Nanomaterials for Medical Applications 55
 - 4.2.2 Nanotechnology Applied to Medicine: A New Medical Discipline for Cardiology? 55
 - 4.2.3 Nano Approaches for Therapeutic Problems 56
 - 4.2.4 Awareness of Risks Introducing Nanotechnology to Patient Treatment 57
 - 4.2.5 Decisional Analysis in Nanomedicine Development 57
- 4.3 Nanoparticles for Treatment of CVD 58
 - 4.3.1 Delivery of Nitric Oxide Small-Molecule Donors 58
 - 4.3.2 PLGA-based Nanoparticles for Gene Delivery 59
 - 4.3.3 Perfluorocarbon Nanoparticles 60
 - 4.3.4 Targeting Vessel Geometry: a Physics-based Approach 60
 - 4.3.5 Nanoparticles Endogenous to Atherosclerosis Pathology 62
- 4.4 Nanotherapeutics in Surgical Interventions 62
 - 4.4.1 Nanoparticles in Drug-eluting Stents 63
 - 4.4.2 Nanopatterning to Improve Stent Integration 64

4.4.3	Nanoparticle Alternatives to Stents	65
4.5	Conclusions	65
	References	66
5	Smart Container for Targeted Drug Delivery	71
	<i>Andreas Zumbuehl</i>	
5.1	Introduction	71
5.2	Liposomes	72
5.2.1	General Characteristics	72
5.2.2	Release of Vesicle-Entrapped Molecules	74
5.2.2.1	Temperature as Trigger	74
5.2.2.2	Ultrasound as Trigger	75
5.2.2.3	Enzymes as Trigger	75
5.2.2.4	pH Changes as Trigger	75
5.2.2.5	Redox Reactions as Trigger	75
5.2.2.6	Photoreactions as Trigger	75
5.2.2.7	Shear Stress as Trigger	76
5.3	Shear Forces and Vesicles	76
5.3.1	Influence of Shear Forces on Vesicles	76
5.3.2	Shear Force-Responsive Vesicles	77
5.4	Conclusions	79
	References	79
6	Human Nano-Vesicles in Physiology and Pathology	83
	<i>Arun Cumpelik and Jürg A. Schifferli</i>	
6.1	Introduction	83
6.2	Nomenclature and Definition	84
6.3	Stimulus for Vesicle Release	85
6.4	Overview of Extracellular Vesicle Biology	86
6.5	NVs of Polymorphonuclear Leukocytes	88
6.6	Erythrocyte NVs	89
6.7	Platelet NVs	91
6.8	Conclusions	92
	Acknowledgment	93
	References	93
7	Challenges and Risks of Nanotechnology in Medicine: An Immunologist's Point of View	97
	<i>János Szebeni</i>	
7.1	Introduction	97
7.2	The Immune Stimulatory Vicious Cycle	98
7.3	The Cause of Immune Recognition of Nanomedicines: Similarity to Viruses	100
7.4	Processes in the Immune Stimulatory Vicious Cycle	101
7.4.1	Complement Activation-Related Pseudoallergy	101

7.4.1.1	Definition and Basics	101
7.4.1.2	Historic Leads	101
7.4.1.3	Foundation of the Concept	104
7.4.1.4	Prevalence, Symptoms, and Features	104
7.4.1.5	Mechanism	105
7.4.2	Immunogenicity and Formation of Antidrug Antibodies	106
7.4.3	Accelerated Blood Clearance (ABC Phenomenon)	107
7.4.3.1	Essentials and Background	107
7.4.3.2	The Immunogenicity of PEG-Conjugated Nanomedicines	107
7.4.4	Mechanism of PEG Immunogenicity	108
7.5	Particle Features Influencing the Immune Side Effects of Nanomedicines	109
7.6	Experimental Analysis of the Adverse Immune Effects of Nanomedicines	110
7.6.1	Measurement of C Activation	110
7.6.2	Prediction of Immunogenicity	110
7.6.3	Prediction of CARPA	111
7.7	Decision Tree to Guide the Evaluation of the CARPAgenic Potential of Nanomedicines	113
7.8	Outlook	114
	References	114

Part Three Second Most Common Cause of Death: Cancer 125

8 Challenges of Applying Targeted Nanostructures with Multifunctional Properties in Cancer Treatments 127

Jean-Luc Coll and Jungyoon Choi

8.1	Introduction	127
8.2	Enhanced Permeability and Retention Effect	128
8.2.1	Biological Point of View	128
8.2.2	Biophysical Perspective	129
8.3	Physicochemical Factors that Influence NP Passive Properties	129
8.3.1	Influence of the Size of the NP	130
8.3.2	Surface Modification and Opsonization	131
8.3.3	Electric Charge	133
8.3.4	Density of Ligands	134
8.4	Targeted NPs	134
8.4.1	Choice of Target Receptor	135
8.4.2	Targeting Folate Receptor Using Folic Acid as an Example of a Small Ligand	135
8.4.2.1	Folic Acid Receptor-Targeted NPs for Drug Delivery	136
8.4.2.2	Folic Acid Receptor-Targeted NPs as Contrast Agents	137
8.4.3	Targeting Integrin with Peptides	138

8.4.3.1	RGD-Targeted Gold NPs	139
8.4.4	Protein-Targeted NPs	141
8.4.4.1	Targeting Transferrin Receptor	141
8.4.4.2	Targeting the Epithelial Growth Factor Receptor	143
8.5	Conclusions	143
	Acknowledgments	144
	References	145
9	Highly Conformal Radiotherapy Using Protons	157
	<i>Antony John Lomax</i>	
9.1	Introduction	157
9.1.1	Principles of Radiotherapy	157
9.1.2	Radiotherapy with X-Rays	157
9.1.3	Radiotherapy Using Protons	159
9.2	Proton Physics	161
9.2.1	Energy Loss	161
9.2.2	Multiple Coulomb Scattering	161
9.2.3	Nuclear Interactions and Secondary Particles	162
9.2.4	Linear Energy Transfer and Relative Biological Effectiveness	163
9.2.5	Density Heterogeneities	163
9.2.6	Generating High-Energy Proton Beams	164
9.2.6.1	Cyclotron	164
9.2.6.2	Synchrotrons	165
9.3	Delivering Proton Therapy	165
9.3.1	Imaging and Treatment Planning	165
9.3.2	Passive Scattering	166
9.3.2.1	Spread-out Bragg Peak	166
9.3.2.2	Single and Double Scattering	167
9.3.2.3	Collimators and Compensators	168
9.3.2.4	Passive Scattering in Practice	168
9.3.3	Pencil Beam Scanning	169
9.3.3.1	Principle of PBS	169
9.3.3.2	PBS versus Passive Scattering	170
9.3.4	Treatment Gentries	171
9.4	Clinical Applications	172
9.4.1	Selected Clinical Indications	172
9.4.1.1	Uveal Melanoma	172
9.4.1.2	Skull-Base Chordomas	174
9.4.1.3	Ependymoma	176
9.5	The Future of Proton Therapy	177
9.5.1	Future is PBS	177
9.5.2	Current and Future Technological Developments	178
9.5.2.1	Treatment Delivery	178
9.5.2.2	Treatment Efficiency	179

9.5.2.3	In-Room/Onboard 3D Imaging and Adaptive Therapy	180
9.5.3	Clinical Future of Proton Therapy	182
9.6	Is There a Role for Nanotechnology in Proton Therapy?	183
9.6.1	Tumor Imaging	184
9.6.2	Dose Enhancement	184
9.6.3	Nanodosimetry	185
9.6.4	Summary	186
	References	186
10	Self-Organization on a Chip: From Nanoscale Actin Assemblies to Tumor Spheroids	191
	<i>Cora-Ann Schoenenberger and Thomas Pfohl</i>	
10.1	Introduction	192
10.2	Microfluidic Cell Culture	197
10.3	Self-Regulated Loading of Cells into Microchambers	197
10.4	2D Cell Culture in Microfluidics	200
10.5	Expanding Microfluidic Cell Culture to the Third Dimension	200
10.6	Microfluidic Biomimetic Models of Cancer	204
10.7	Future Perspectives	204
	Acknowledgments	205
	References	205
11	The Nanomechanical Signature of Tissues in Health and Disease	209
	<i>Daphne O. Asgeirsson, Philipp Oertle, Marko Loparic, and Marija Plodinec</i>	
11.1	Summary	209
11.2	Tissue Mechanics Across Length Scales	210
11.3	Atomic Force Microscopy (AFM) in Cell and Tissue Biology	211
11.3.1	Basic Operating Principles of AFM	211
11.3.2	Scale Dependency and Resolution	212
11.3.3	AFM in Cell Biology	215
11.4	The Nanomechanical Signature of Articular Cartilage	218
11.4.1	Articular Cartilage Composition and Function	218
11.4.2	The Nanomechanics of Articular Cartilage	219
11.4.3	The Nanomechanical Signature of Osteoarthritis	221
11.5	The Nanomechanical Signature of Mammary Tissues	224
11.5.1	Mammary Gland Composition and Mechanics	224
11.5.2	The Nanomechanical Signature of Breast Cancer	225
11.6	AFM – The Diagnostic and Prognostic Tool of the Future	229
	Acknowledgments	232
	Competing Financial Interests	232
	References	232

**Part Four Most Common Diseases: Caries, Musculoskeletal Diseases,
Incontinence, Allergies 241**

**12 Revealing the Nano-Architecture of Human Hard and Soft Tissues by
Spatially Resolved Hard X-Ray Scattering 243**

Hans Deyhle and Bert Müller

- 12.1 Introduction 243
- 12.2 Spatially Resolved Hard X-Ray Scattering 244
 - 12.2.1 Introductory Remarks on X-Ray Scattering 244
 - 12.2.2 Experimental Setup for X-Ray Scattering 246
 - 12.2.3 Two-Dimensional Scanning Small-Angle X-Ray Scattering 248
 - 12.2.4 Scattering Pattern Analysis 249
 - 12.2.5 Tissue Preparation 250
- 12.3 Nanoanatomy of Human Hard and Soft Tissues 251
 - 12.3.1 Human Tooth 251
 - 12.3.2 Femoral Head 254
 - 12.3.3 Breast Tumor 256
 - 12.3.4 Brain Tissue 256
- 12.4 Conclusions and Outlook 259
- References 259

13 Regenerative Dentistry Using Stem Cells and Nanotechnology 263

Thimios A. Mitsiadis and Giovanna Orsini

- 13.1 Introduction 263
- 13.2 Repair of Dental Tissues 264
- 13.3 Dental Stem Cells and Their Regenerative Potential 265
- 13.4 Regenerative Dentistry 267
- 13.5 Nanotechnology in Dentistry 269
- 13.6 Nanoscale Surface Modifications of Dental Biomaterials 270
 - 13.6.1 Approaches for Nanoscale Surface Modification in
Dental Implants 270
 - 13.6.2 Biological Surfaces Principles 271
 - 13.6.3 Cellular Responses to Nanostructured Surfaces 272
 - 13.6.4 Clinical Applications of Nanostructured Dental Implants 273
 - 13.6.5 Nanomodifications of Bone Replacements Materials 275
 - 13.6.6 Nanofillers in Dental Restorative Materials 276
 - 13.6.7 Nanoscale Modification in the Treatment of Dentin Hypersensitivity
and Enamel Remineralization 278
- 13.7 Concluding Remarks 279
 - Acknowledgments 280
 - References 280

14 Nanostructured Polymers for Medical Applications 293

Prabitha Urwyler and Helmut Schift

- 14.1 Introduction 293

14.1.1	Nanostructured Polymers – A Promising Approach in Biomedical Applications	293
14.1.2	Strategies for Creation of Surface Nanotopographies	294
14.2	Applications of Nanostructures	295
14.2.1	Which Nanoeffects Will Be Exploited for Biomedical Applications?	296
14.2.1.1	Combined Effects	298
14.2.1.2	Cell Proliferation and Differentiation	298
14.2.1.3	Protein Nanopattern	300
14.2.2	Mimicking Nature	300
14.2.3	Gecko-Inspired Bandage as an Example	301
14.3	Processes for Generation of Nanotopographies	301
14.3.1	Top-Down Manufacturing by Origination, Tooling, Replication	302
14.3.2	Bottom-Up Manufacturing By Self-Organization and Surface Postprocessing	303
14.4	Surface Patterning of Microcantilevers Using Mold Inlays	303
14.5	Surface Patterning Using Plasma Etching	306
14.6	Cell Response to Surface Patterning	308
14.7	Conclusion	309
	References	310
15	Nanotechnology in the Treatment of Incontinence	315
	<i>Vanessa Leung and Christian Gingert</i>	
15.1	Urinary Incontinence	316
15.1.1	Urinary Incontinence Etiology	316
15.1.2	Urinary in-/Continence Assessment	316
15.1.3	Physics of Urinary Continence	318
15.1.4	Tissue Engineering and Sling Material for Sphincter Regeneration	319
15.2	Fecal Incontinence	321
15.2.1	Fecal Incontinence Etiology	321
15.2.2	Physics of Fecal Continence	321
15.2.3	Fecal in-/Continence Assessment	322
15.2.4	Tissue Engineering for Sphincter Regeneration	323
15.2.5	Dielectric Elastomer Actuators for Sphincter Replacement	324
	References	327
16	Nanomedicine in Dermatology: Nanotechnology in Prevention, Diagnosis, and Therapy	329
	<i>Kathrin Scherer Hofmeier and Christian Surber</i>	
16.1	Introduction	329
16.2	Nature of Nanoparticles	330
16.2.1	Soft Particles	330
16.2.2	Rigid Particles	331
16.2.3	Surface Functionalization	332
16.2.4	Formulations with Nanoparticles	333

16.3	Absorption of Nanoparticles through Skin	333
16.3.1	Absorption Pathways	333
16.3.2	Risk and Safety Considerations	335
16.4	Nanoparticles in Prevention, Diagnosis, and Therapy	336
16.4.1	Prevention	336
16.4.1.1	Antisepsis	336
16.4.1.2	Photoprotection, Color, and Light Reflectance Control	337
16.4.1.3	Preventive Care	338
16.4.1.4	Odor Neutralizers	338
16.4.1.5	Vaccines	338
16.4.2	Diagnosis and Monitoring	338
16.4.3	Therapy	340
16.4.3.1	Sebaceous Gland Disorders	340
16.4.3.2	Hair Disorders	340
16.4.3.3	Inflammatory Disorders	341
16.4.3.4	Cancer	341
16.4.3.5	Surgery	343
16.5	Regulatory Issues	344
16.6	Public Perception of Nanoparticles in Topicals	344
16.7	Conclusions and Future Perspectives	345
	References	347

Part Five Benefiting Patients 357

17 Therapeutic Development and the Evolution of Precision Medicine 359

Gareth D. Healey and R. Steven Conlan

17.1	Origins of Nanomedicine	359
17.2	Global Nanomedicine Market	360
17.3	Nanomedicine Cabinet	361
17.4	Application of Nanomedicine – A Paradigm Shift	365
17.5	Targeted Drug Discovery and the Human Kinome	367
17.6	Translation from Discovery to the Clinic	369
17.7	Evolution of Kinase Inhibitors	370
17.8	Nanoparticle Delivery	372
17.9	Conclusions	374
	References	374

18 Benefit from Nanoscience and Nanotechnology: Benefitting Patients 379

Bert Müller and Marcel H. Van de Voorde

Index 383

